Preclinical investigation reveals a receptor-mediated pathway limiting PD-1 surface interactions, suggesting improved anti-PD-1 antibody efficacy.
T cells. Our study demonstrates a novel mechanism for reducing cell surface levels of PD-1 and limiting the inhibitory targeting by PD-L1/2 and thereby enhancing the efficacy of anti-PD-1 Ab in restoring T cell functionality.
No takes yet. Share an insight, caveat, or question.
Joo et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: